Preparation of Chitosan Lactate Sponges with Uniform Vertical Pores and Fitted Analysis of Release Medicine Model in vitro

doi:10.3969/j.issn.0251-0790.2012.04.035

Abstract

Abstract: Chitosan lactate(LCH) was obtained by reacting with lactic acid based on chitosan(CH). The products were found to be superior to original chitosan as far as water solubility was concerned. With the structure-directing agent tertiary butyl alcohol(TBA) in the vertical temperature controlled device, uniform and vertical pores structure in sponges were obtained upon freeze-drying. Different diameter form sponge samples were made by controlling the concentration of TBA. Then, drug delivering model of sponges samples with degradation and dissolution function was studied with erythromycin as model drug in vitro. The results demonstrate that drug delivering process of sponge samples is divided into two stages: matrix dissolution controlled-release stage and drug after-diffusion stage. Matrix dissolution controlled-release stage is very good to fit the couarraze drug delivering model.

Key words: Chitosan lactate(LCD), Tertiary butyl alcohol(TBA), Dissolution controlled-release, Fitted analysis of release medicine model in vitro

CLC Number:

O636

TrendMD:

YU Fei, XI Ting-Fei, ZHANG Shu-Jiang, ZHANG Zhi-Xiong, LAI Chen. Preparation of Chitosan Lactate Sponges with Uniform Vertical Pores and Fitted Analysis of Release Medicine Model in vitro[J]. Chem. J. Chinese Universities, 2012, 33(04): 843.

References

[1] Muzzarelli R. A. A., Muzzarelli C.. Advanced in Polymer Science[J], 2005, 18(6): 151-209 [2] Kumar M. N. V. R., Muzzarelli R. A. A., Muzzarelli C., Sashiwa H., Domb A.. J. Chemical Reviews[J], 2004, 104(12): 6017-6084 [3] Yusof N. L. B. M., Wee A., Lim L. Y., Khor E.. Journal of Biomedical Materials Research(Part A)[J], 2003, 66A(2): 224-232 [4] Kurita K., Amemiya J., Mori T., Nishiyama Y.. Polymer Bulletin[J], 1999, 42(4): 387-393 [5] WANG Yin-Song(王银松), HAN Yue-Lian(韩月莲), LI Ying-Xia(李英霞), WANG Yu-Mei(王玉玫), LI Rong-Shan(李荣珊). Chem. J. Chinese Universities(高等学校化学学报)[J], 2007, 28(6): 1092-1097 [6] Kasraian K., Deluca P. P.. Pharmaceutical Research[J], 1995, 12(4): 491-495 [7] Teagarden D. L., Petre W. J., Gold P. M.. Method for Preparing Stabilized Prostaglandin, US 5770230, 1998-06-23 [8] Telang C., Suryanarayanan R.. Pharmaceutical Research[J], 2005, 22(1): 153-160 [9] Altiok D., Altiok E., Tihminlioglu F.. J. Mater. Sci.: Mater. Med.[J], 2010, 21: 2227-2236 [10] Dai M., Zheng X. L., Xu X., Kong X. Y., Li X. Y., Guo G., Luo F., Zhao X., Wei Y. Q., Qian Z. Y.. Journal of Biomedicine and Biotechnology[J], 2009, 595826-1-595826-8 [11] Colonna C., Genta I., Perugini P., Pavanetto F., Modena T., Valli M., Muzzarelli C., Conti B.. AAPS Pharm. Sci. Tech.[J], 2006, 7(3): E107-E113 [12] Phaechamud T., Charoenteeraboon J.. AAPS Pharm. Sci. Tech.[J], 2008, 9(3): 829-835 [13] LIU Ying(刘英), CHEN Jie(陈杰), LI Zhan(李展). Chinese Pharmaceutical Affairs(中国药事)[J], 1999, 13(3): 188-189 [14] Narayan B., Hassna R. R., Shinn H. C., Miqin Z.. Int. J. Nanomedicine[J], 2006, 1(2): 181-187 [15] Sunee T., Sirirat W., Praneet O., Auayporn A., Jurairat N., Uracha R.. AAPS Pharm. Sci. Tech.[J], 2010, 11(1): 64-72 [16] Miya M., Iwamoto R., Yoshikawa S.. Int. J. Biol. Macromol.[J], 1980, 2(5): 323-324 [17] Ogawa K., Hirano S., Miyanishi T., Yui T., Watanabe T.. Macromolecules[J], 1984, 17(4): 973-975 [18] Johnee R., Kristine N. T., Dahiya R., Rubinsky B.. Breast Cancer Res. Treat.[J], 1999, 53(2): 185-192 [19] ZHANG Ji-Wen(张继稳), GU Jing-Kai(顾景凯). Controlled/Sustaine Release Dosage Form Pharmacodynamics(缓控释制剂药物动力学)[M], Beijing: Science Press, 2009: 42 [20] Heller J., Baker R. W.. Controlled Release of Bioactive Materials[M], New York: Academic Press, 1980: 1-18 [21] Charlier A., Leclerc B., Couarraze G.. International Journal of Pharmaceutics[J], 2000, 200: 115-120